Clinical trials: Heart Transplant Recipient
Heart Transplantation
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
In this study two immunosuppressive regimens (everolimus in combination with cyclosporine microemulsion and mycophenolate mofetil with cyclosporine microemulsion) with reduced dose cyclosporine microemulsion are compared in…
- Trial name
- NCT00170859
- Testing
- Everolimus
- Where
- Germany
- Sponsor
- Novartis Pharmaceuticals
Heart Transplant Recipients
Autonomic Cardiovascular Control After Heart Transplantation
The purpose of this prospective study is to investigate denervation (ie. surgical cutting of autonomic nerves) and re-innervation (ie. growth of autonomic nerves) in heart transplant recipients. More specifically, we focus on: 1.
- Trial name
- AccHeart (NCT01759966)
- Where
- Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Microsporidiosis Intestinal, Heart Transplant Infection
Intestinal Microsporidiosis in French Heart Transplant Recipients (CARMIC)
The investigators propose to carry out a national retrospective study to collect epidemiological, biological, clinical and therapeutic data on microsporidiosis among heart transplant patients.
- Trial name
- CARMIC (NCT06986980)
- Where
- France
- Volunteers
- 39 people
- Sponsor
- University Hospital, Clermont-Ferrand
Heart Transplantation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
Following heart transplantation (HTx), lifelong immunosuppressive treatment is required to prevent the immune system from attacking, damaging, and rejecting the donor hear (allograft).
- Trial name
- TRANSCEND (NCT07886489)
- Testing
- Donor-derived cell free DNA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Renal Transplant
24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant…
- Trial name
- EVITA (NCT01169701)
- Testing
- Everolimus, Tacrolimus, Mycophenolic acid (MPA)
- Where
- 9 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Recipient, Heart Transplant Recipient
Pharmacokinetics of Mmf and Valganciclovir
The primary objective of this study is to determine whether a clinically significant PK drug interaction ( a 30% difference in the AUC of MPA) exists between mycophenolate mofetil (under steady state conditions) and VGCV in renal…
- Trial name
- NCT00189150
- Testing
- Mycophenolate mofetil, Valganciclovir
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function
This is a multi-center, prospective, single cohort, observational study of pediatric heart transplant recipients designed to determine the impact of preformed versus de novo human leukocyte antigen (HLA) donor-specific antibodies…
- Trial name
- NCT02752789
- Where
- 9 sites in United States, Canada
- Volunteers
- 407 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipient
Clinical Significance of 64-slice Multidetector Coronary CT Angiography to Evaluate the Prevalence and Severity of Coronary Artery Disease in Renal Transplant Recipients
The aim of this study is to evaluate the clinical usefulness of 64-slice multidetector coronary CT angiography (MDCTA) in renal transplant recipients who had no previous coronary artery disease (CAD).
- Trial name
- NCT01753505
- Testing
- 64-slice Multidetector coronary CT angiography
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Yonsei University
Cardiac Allograft Vasculopathy
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
Hypothesis 1: Treatment of heart transplant recipients with sildenafil, a PDE-5 inhibitor, will improve small artery elasticity (SAE) when compared to placebo.
- Trial name
- NCT01812434
- Testing
- Sildenafil
- Where
- United States
- Sponsor
- University of Minnesota
Cardiac Allograft Vasculopathy
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
The purpose of this study is to test the hypothesis that administering Thymoglobulin® induction therapy early after transplant prevents the development of cardiac allograft vasculopathy (CAV).
- Trial name
- NCT01157949
- Testing
- Thymoglobulin
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function.
- Trial name
- NCT01278745
- Testing
- Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
- Where
- 24 sites in United States
- Volunteers
- 362 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mayo Clinic
Immunosuppression
Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
This was a study to compare less intense immunosuppression with a more traditional approach. The hypothesis was that less immunosuppression will provide similar protection against rejection than typical 2-3 drug therapy.
- Trial name
- TICTAC (NCT00299221)
- Testing
- Tacrolimus, combination therapy
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Newark Beth Israel Medical Center
Heart Transplant Recipients
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Iron deficiency is prevalent in heart transplant recipients, and may be associated with reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous iron isomaltoside on exercise capacity, muscle…
- Trial name
- IronIC (NCT03662789)
- Testing
- Iron Isomaltoside 1000
- Where
- Norway
- Volunteers
- 102 people
- Sponsor
- Oslo University Hospital
Heart Transplantation, Exercise Capacity
Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients
The purpose of this study is to investigate the effect of physical training on work capacity and vascular function after heart transplantation, cardiac transplant recipients are randomized to 8 weeks of intense physical training…
- Conditions
- Heart Transplantation, Exercise Capacity, Endothelial Function
- Trial name
- NCT01028599
- Testing
- Intensive physical exercise
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Transplant Failure, Kidney Failure
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Kidney failure is common in heart transplant recipients and is a major cause of morbidity and mortality. Sodium-glucose transporter 2 (SGLT2) inhibitors were developed as antidiabetics but were subsequently shown to reduce the…
- Trial name
- DAPARHT (NCT05321706)
- Testing
- Dapagliflozin 10 mg
- Where
- 6 sites in Netherlands, Norway and 1 more
- Volunteers
- 430 people
- Sponsor
- Oslo University Hospital
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
Heart Cancer, Kidney Cancer
Cancer Development In Organ Transplant Recipients
The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis.
- Conditions
- Heart Cancer, Kidney Cancer, Lung Cancer, Pancreas Cancer
- Trial name
- NCT02333279
- Where
- Switzerland
- Volunteers
- 1,800 people
- Sponsor
- University of Zurich
Kidney Transplantation, Liver Transplantation
Quality of Life in Pediatric Transplant Recipients
Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.
- Conditions
- Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation
- Trial name
- NCT00209196
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Emory University
Heart Transplantation, Hypercholesterolemia
Fluvastatin After Heart Transplantation
Statin therapy is a treatment with a proven positive impact on survival after heart transplantation. However, it is unclear whether the beneficial effect of this class of drugs depends solely on their LDL-lowering properties or…
- Trial name
- NCT00421005
- Testing
- fluvastatin
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- University of Bologna